Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and parkinson's disease

Research output: Contribution to journalReview articlepeer-review

48 Citations (Scopus)


A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor γ, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinson's disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinson's disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinson's disease on the effects of NSAIDs.

Original languageEnglish
Pages (from-to)1428-1434
Number of pages7
JournalCurrent Pharmaceutical Design
Issue number14
Publication statusPublished - May 2008


  • Cyclooxygenase
  • Dopamine quinone
  • Inflammation
  • Neuroprotection
  • Nitric oxide
  • Nonsteroidal anti-inflammatory drugs
  • Parkinson's disease
  • Peroxisome proliferator-activated receptor γ

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and parkinson's disease'. Together they form a unique fingerprint.

Cite this